GILD vs VRTX
GILD and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $212.04B | $141.70B |
| P/E (TTM) | 25.2 | 32.6 |
| P/B | 16.26 | 7.00 |
| P/S | 7.2x | 11.8x |
| Dividend yield | 1.89% | — |
| Revenue | $30.99B(TTM) | $12.59B(TTM) |
| Revenue growth (YoY) | 2.4% | 8.9% |
| Net income | -$3.86B(TTM) | $4.41B(TTM) |
| Earnings growth (YoY) | 1672.9% | 838.1% |
| EPS, diluted | $-3.13(TTM) | $17.17(TTM) |
| EBIT margin | 34.0% | 34.8% |
| ROE | 65.3% | 19.5% |
| ROIC | 25.7% | 25.0% |
| 1y total return | +47.1% | +33.1% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: GILD frente a VRTX
| Métrica | GILD | VRTX |
|---|---|---|
| Valor final | $29.7K | $65.8K |
| Retorno total | +197.3% | +557.5% |
| CAGR | +11.1% | +20.0% |
| Volatilidad | 25.6% | 32.6% |
| Sharpe | 0.38 | 0.60 |
| Sortino | 0.56 | 0.88 |
| Caída máxima | -30.5% | -41.6% |
Basado en 2600 días de negociación comunes, 2016-06-29 → 2026-10-30 · tasa libre de riesgo 4.16% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)